Aging Blood Vessels: Unlocking the Secrets of Metabolic Disorders
A groundbreaking discovery has emerged from the Cedars-Sinai Center for Advanced Gerotherapeutics, shedding light on the intricate relationship between aging blood vessels and metabolic disorders. Researchers have uncovered a crucial role played by aged blood vessel cells in the development of diabetes and other metabolic issues, opening up new avenues for treatment.
The study, published in Cell Metabolism, reveals a fascinating connection between obesity and the accumulation of senescent cells, which are cells that have stopped dividing but remain alive. These senescent cells, as explained by Masayoshi Suda, MD, PhD, an assistant professor of Medicine at Cedars-Sinai and the lead author, can either aid in wound healing or contribute to age-related diseases, depending on their origin and the factors influencing them.
The research team's previous work demonstrated the potential of senolytics, drugs that eliminate senescent cells, in improving metabolic function. Building on this, the current study focused on senescent blood vessel cells, which were selectively removed from obese laboratory mice. The results were remarkable: inflammation and fat mass were reduced, and blood sugar levels improved.
However, the story doesn't end there. When senescent blood vessel cells were transplanted into lean laboratory mice, a surprising outcome emerged. These mice developed inflammation in their fat tissue and experienced metabolic dysfunction. This finding highlights the critical role of these cells in maintaining metabolic balance.
The investigators further explored the mechanism behind this phenomenon, discovering that senescent blood vessel cells release high levels of inflammatory molecules. To combat this, they treated the mice with fisetin, a naturally occurring senolytic compound. The results were encouraging, as the mice exhibited a decline in senescent blood vessel cells and showed improved diabetic symptoms.
The study's implications extend beyond the laboratory. Suda and his team plan to test this approach in clinical trials, aiming to target senescent cells safely in humans. By doing so, they believe they can address not only diabetes but also a range of age-related conditions, marking a significant step forward in the field of gerotherapeutics.
